News & stories

News | Sep 23, 2024

Diabetes medication must be made affordable and accessible

Eli Lilly, Novo Nordisk, and Sanofi must drop their prices and stop blocking generic manufacturers from entering the market.

News | Jul 17, 2024

MSF welcomes Indian rejection of J&J patent application for pediatric TB drug

Decision will allow other drugmakers to help boost the supply of this lifesaving medicine.

Story | Sep 18, 2023

The long and winding road to affordable access to a key TB drug

Christophe Perrin, the MSF Access Campaign‘s TB advocacy pharmacist, discusses the need for secure affordable access to improved TB medicines.

News | Sep 12, 2023

J&J and Cepheid must expand access to TB drug and tests

TB is curable but remains the world’s leading infectious disease killer as pharma corporations stand in the way of affordable medical tools

Story | Jul 13, 2023

Johnson & Johnson deal falls short for people with TB

Johnson & Johnson must end its patent monopoly on bedaquiline so generic versions of this lifesaving drug can be widely produced.

News | Apr 26, 2023

J&J must stop blocking generic versions of lifesaving TB drug

J&J’s patent monopoly continues to keep bedaquiline out of reach.

News | Mar 23, 2023

MSF applauds rejection of J&J attempt to extend TB drug patent

The rejection of the salt form of bedaquiline is welcome news for people with drug-resistant tuberculosis.

News | Nov 08, 2022

MSF: Opportunity to increase access to newer, safer TB drugs is at risk

With newer TB drugs set to go off patent in 2023, drugmakers J&J, Otsuka, and TB Alliance must remove additional barriers that block more affordable versions from entering the market.

News | Oct 18, 2021

EndTB clinical trial for multidrug-resistant tuberculosis concludes enrollment

News | Sep 03, 2021

MSF: Pediatric formulations of lifesaving TB medicines must be more widely affordable and available